ID   UM-UC-9
AC   CVCL_2753
SY   UMUC9; UC-9; University of Michigan-Urothelial Carcinoma-9
DR   BTO; BTO:0004990
DR   cancercelllines; CVCL_2753
DR   Cell_Model_Passport; SIDM01401
DR   Cosmic; 846274
DR   Cosmic; 1082650
DR   Cosmic; 2037971
DR   Cosmic; 2700986
DR   DepMap; ACH-001416
DR   ECACC; 08090505
DR   GEO; GSM136260
DR   GEO; GSM1574565
DR   Wikidata; Q54990997
RX   PubMed=16469639;
RX   PubMed=18812553;
RX   PubMed=19375735;
RX   PubMed=24018021;
RX   PubMed=25997541;
RX   PubMed=27270441;
RX   PubMed=28196595;
RX   PubMed=29732388;
WW   https://tcpaportal.org/mclp/
WW   https://www.synapse.org/UC25
CC   Part of: BLA-40 bladder carcinoma cell line panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: UBC-40 urothelial bladder cancer cell line index.
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Ile2888Thr (c.8663T>C); ClinVar=VCV000245842; Zygosity=Heterozygous (PubMed=27270441).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Leu348fs (c.1044delG); Zygosity=Unspecified (PubMed=27270441).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Caution: PubMed=27270441 reports a STR profile (CSF1PO: 10; D13S317: 11; D16S539: 9,11; D5S818: 13; D7S820: 8,10; TH01: 7; TPOX: 8; vWA: 17,19) which is completely different from that of DepMap and ECACC.
CC   Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.
ST   Source(s): DepMap=ACH-001416; ECACC=08090505
ST   Amelogenin: X
ST   CSF1PO: 12,13
ST   D13S317: 11,13
ST   D16S539: 11,13
ST   D18S51: 16,17
ST   D21S11: 29
ST   D3S1358: 14,17
ST   D5S818: 12
ST   D7S820: 9,11
ST   D8S1179: 12,14 (DepMap=ACH-001416)
ST   D8S1179: 14 (ECACC=08090505)
ST   FGA: 22,25,26
ST   Penta D: 10
ST   Penta E: 7,12
ST   TH01: 9
ST   TPOX: 11
ST   vWA: 16,17
DI   NCIt; C4912; Bladder carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 25
//
RX   PubMed=16469639; DOI=10.1016/S0022-5347(05)00323-X;
RA   Sabichi A.L., Keyhani A., Tanaka N., Delacerda J., Lee I.-L., Zou C.-P.,
RA   Zhou J.-H., Benedict W.F., Grossman H.B.;
RT   "Characterization of a panel of cell lines derived from urothelial
RT   neoplasms: genetic alterations, growth in vivo and the relationship of
RT   adenoviral mediated gene transfer to coxsackie adenovirus receptor
RT   expression.";
RL   J. Urol. 175:1133-1137(2006).
//
RX   PubMed=18812553; DOI=10.1093/jnci/djn304;
RA   Park H.-S., Park W.S., Bondaruk J., Tanaka N., Katayama H., Lee S.,
RA   Spiess P.E., Steinberg J.R., Wang Z., Katz R.L., Dinney C.P.N.,
RA   Elias K.J., Lotan Y., Naeem R.C., Baggerly K., Sen S., Grossman H.B.,
RA   Czerniak B.;
RT   "Quantitation of Aurora kinase A gene copy number in urine sediments
RT   and bladder cancer detection.";
RL   J. Natl. Cancer Inst. 100:1401-1411(2008).
//
RX   PubMed=19375735; DOI=10.1016/j.juro.2009.01.108;
RA   Chiong E., Dadbin A., Harris L.D., Sabichi A.L., Grossman H.B.;
RT   "The use of short tandem repeat profiling to characterize human
RT   bladder cancer cell lines.";
RL   J. Urol. 181:2737-2748(2009).
//
RX   PubMed=24018021; DOI=10.1016/j.eururo.2013.08.052;
RA   Allory Y., Beukers W., Sagrera A., Flandez M., Marques M., Marquez M.,
RA   van der Keur K.A., Dyrskjot L., Lurkin I., Vermeij M., Carrato A.,
RA   Lloreta J., Lorente J.A., Carrillo-de-Santa-Pau E., Masius R.G.,
RA   Kogevinas M., Steyerberg E.W., van Tilborg A.A.G., Abas C.,
RA   Orntoft T.F., Zuiverloon T.C.M., Malats N., Zwarthoff E.C., Real F.X.;
RT   "Telomerase reverse transcriptase promoter mutations in bladder
RT   cancer: high frequency across stages, detection in urine, and lack of
RT   association with outcome.";
RL   Eur. Urol. 65:360-366(2014).
//
RX   PubMed=25997541; DOI=10.1186/s12864-015-1450-3;
RA   Earl J., Rico D., Carrillo-de-Santa-Pau E., Rodriguez-Santiago B.,
RA   Mendez-Pertuz M., Auer H., Gomez G., Grossman H.B., Pisano D.G.,
RA   Schulz W.A., Perez-Jurado L.A., Carrato A., Theodorescu D.,
RA   Chanock S.J., Valencia A., Real F.X.;
RT   "The UBC-40 Urothelial Bladder Cancer cell line index: a genomic
RT   resource for functional studies.";
RL   BMC Genomics 16:403.1-403.16(2015).
//
RX   PubMed=27270441; DOI=10.1038/onc.2016.172;
RA   Nickerson M.L., Witte N., McGee Im K., Turan S., Owens C.R., Misner K.,
RA   Tsang S.X., Cai Z.-M., Wu S., Dean M., Costello J.C., Theodorescu D.;
RT   "Molecular analysis of urothelial cancer cell lines for modeling tumor
RT   biology and drug response.";
RL   Oncogene 36:35-46(2017).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29732388; DOI=10.3233/BLC-180167;
RA   Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.;
RT   "Systematic review: characteristics and preclinical uses of bladder
RT   cancer cell lines.";
RL   Bladder Cancer 4:169-183(2018).
//